Chaime Orlev

Chaime Orlev is the current CFO at Kamada. Prior to this, they served as VP Finance and Administration at Chiasma from July 2010 to September 2016. Orlev was part of the management team who led the 2015 +$100M IPO as well as negotiated and closed the agreement for the licensing of lead product to F. Hoffmann-La Roche for $65M down payment, $510M of milestone payments and double digit tiered royalties. Chaime was also part of the closing of two private equity financing rounds for a total of $70M. Chaime's responsibilities included vendors (CMO, CRO, medical centers, laboratories, etc) engagement and contract negotiations.

From January 2008 to December 2009, Orlev served as VP Finance and Administration, CFO at Oramed Pharmaceuticals Inc. During their time there, they were responsible for all financial reporting, SEC filings, investor relations, treasury functions, and corporate finance.

Orlev then served as CFO at Gammacan International, Inc from January 2005 to December 2008 where they were responsible for all aspects of finance and accounting. Some of their notable achievements include leading the company through an IPO in 2006 and increasing revenues by 50% in 2007.

Chaime Orlev earned their EMBA from Tel Aviv University and completed an internship at Shachak Peer Reznick & CO. Chaime holds a BA in Accounting from The College of Management Academic Studies.

Chaime Orlev works with Orit Pinchuk - VP, Regulatory Affairs, Naveh Tov - VP, Clinical Development and Medical Director for Pulmonary Diseases, and Eran Nir - VP Operations. Chaime Orlev reports to Amir London, CEO.